United States · Business magazines · Quartz

Pfizer is tapping Blackstone for up to $1.5 billion to fund its weight-loss drug

Published by Quartz · United States 32 min ago

Pfizer is tapping Blackstone for up to $1.5 billion to fund its weight-loss drug — Quartz

Detailed summary

Blackstone would be eligible for milestone payments tied to U.S. approval of monthly berobenatide, while Pfizer keeps full control

Read the full article on Quartz Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (qz.com)

Also worth reading

The cracks in venture are beginning to show, just as Anthropic gets ready to IPO

How to Protect an Aging Parent’s Finances Without Conflict

After 28 Years, Apple Is Shutting Down Its Most Valuable Customer Support Tool

The best AI lab in business is not for sale—you already own it

Markets Insider (Business Insider)

DarioHealth GAAP EPS of $0.73 beats by $1.68, revenue of $5.31M beats by $0.1M

In Healthcare, Legacy And Values Are The Foundation For Innovation And Growth